Checkpoint Therapeutics, Inc. (CKPT) Dividend History

Company News

• Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

  Fortress Biotech announced the closing of the sale of its subsidiary Checkpoint Therapeutics to Sun Pharmaceutical Industries Limited. The transaction will generate approximately $28 million for Fortress and a 2.5% royalty on net sales of Checkpoint's FDA-approved drug UNLOXCYT.

  Benzinga

  Featured Companies: FBIO FBIOP
• SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Buyout Offer and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and Options

  Kaskela Law LLC is investigating the fairness of Checkpoint Therapeutics, Inc.'s proposed acquisition by Sun Pharmaceutical Industries Ltd. at $4.10 per share plus a contingent value right, as the buyout price is lower than analysts' price targets.

  GlobeNewswire Inc.
• Best Penny Stocks To Buy? 4 To Watch With Big News This Week

  Penny Stocks – How News Makes These Small Caps Soar or Plunge… The post Best Penny Stocks To Buy? 4 To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: ACRS BMY
• 2 Biotech Stocks That Could Be 10-Baggers in 2022

  These two clinical-stage biotechs have major upcoming catalysts that could catapult their shares higher.

  The Motley Fool

  Featured Companies: AXSM XBI
• Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

  Checkpoint Therapeutics (CKPT) is approaching a critical data readout for Cosibelimab, presenting a great Buy opportunity.

  Seeking Alpha